Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
The most effective method to Pick the Best Material Organization: Insider Tips - 2The 10 Most Famous Style Minutes on Honorary pathway
- 3The Most Compelling Innovation Advancements Somewhat recently
- 4When Would it be a good idea for you to Look for Help from a Criminal Legal counselor?
- 5‘I love this work, but it’s killing me’: The unique toll of being a spiritual leader today
- Europe: 4 Urban communities for a Paramount Social Experience
- NASA probe captures stunning photos of Earth and moon on the way to infamous asteroid Apophis
- Holiday travel: Best days to hit the road as 110 million Americans expected to drive over Christmas and New Year's
- Aluminum salts emerge as likely target as health officials scrutinize childhood vaccines
- Doctor's orders: Eat ice cream, and other tips for a long and healthy life
- Red Crescent: More than 100,000 civilian structures damaged in Iran
- Eight Muslim nations condemn Israel's 'dangerous' new death penalty law
- Shrewd Home Gadgets to Save Energy
- IDF kills four terrorists equipped with weapons, surveillance gear near Gaza's Yellow Line
